natgillin/translations-raw huggingface dataset:
Bolnike je treba poučiti, da se v primeru, da se med ali po zdravljenju s porfirini pojavijo fotosenzitivne reakcije, posvetujejo z zdravnikom.
Patients should be instructed to seek medical advice if signs/symptoms suggestive of photosensitivity occur during or after therapy with porfimer.
Bolnike je treba redno spremljati zaradi možnega razvoja motenj nadzora impulzov.
Patients should be regularly monitored for the development of impulse control disorders.
Bolnike je treba redno spremljati, da bi odkrili morebiten razvoj manije in delirija.
Patients should be regularly monitored for the development of mania and delirium.
Bolnike s potrjeno diagnozo pridobljene hemofilije morajo obravnavati in zdraviti zdravniki specialisti, zdravljenje s klopidogrelom pa je treba prekiniti.
Patients with a confirmed diagnosis of acquired haemophilia should be managed and treated by specialists, and clopidogrel should be discontinued.
Bolnike so izključili iz raziskave, če so imeli invazivni rak požiralnika, rak v anamnezi, razen kožnega raka, ki ni bil melanom, ali če so poprej dobili PDT v požiralnik.
Patients were excluded from the study if there was a presence of invasive oesophageal cancer, if they had a history of cancer other than non- melanoma skin cancer or if they had received prior PDT to the oesophagus.
Bolnike so randomizirali, da so subkutano prejemali ustekinumab v odmerkih po 45 mg, 90 mg ali placebo v tednu 0 in 4 in nato na vsakih 12 tednov.
Patients were randomised to receive treatment with ustekinumab 45 mg, 90 mg, or placebo subcutaneously at Weeks 0 and 4 followed by every 12 weeks (q12w) dosing.
Bolnike so spremljali 30 dni.
The patients were followed for 30 days.
Bolnike z boleznijo pljuč ali srca ali s tovrstno boleznijo v anamnezi je treba previdno zdraviti.
Patients with pulmonary or cardiac medical illness or a history of such illness should be treated with caution.
Bolnike z majhnim številom belih krvnih celic je treba skrbno spremljati zaradi možnosti infekcije in nevarnosti drugih zapletov nevtropenije ter zdraviti, kot je indicirano (npr. z antibiotiki, granulocitne kolonije spodbujajočim faktorjem (G-CSF)).
Patients with low white blood cell counts should be monitored carefully for infection and risk of other complications of neutropaenia and treated as medically indicated (e.g., with antibiotics, granulocyte-colony stimulating factor [G-CSF]).
Bolnike, ki imajo težave z anoreksijo, astenijo, navzeo, bruhanjem, drisko, stomatitisom ali gastrointestinalno obstrukcijo, je treba pozorno spremljati glede znakov dehidracije.
Patients with anorexia, asthenia, nausea, vomiting, diarrhoea, stomatitis, and gastrointestinal obstruction should be monitored closely for signs of dehydration.
Bolnike, ki prejemajo zdravilo STELARA, je treba natančno spremljati, da bi pri njih lahko ugotovili znake in simptome aktivne tuberkuloze, tako med zdravljenjem kot po njem.
Patients receiving STELARA should be monitored closely for signs and symptoms of active tuberculosis during and after treatment.
Bolnike, ki so dobili večje odmerke od priporočenih (glejte poglavje 4.2), je treba natančno kontrolirati, ker so pri takšnih bolnikih opažali okvaro delovanja ledvic (vključno z ledvično odpovedjo) in nepravilnosti elektrolitov v serumu (vključno s kalcijem, fosforjem in magnezijem).
Patients who have received doses higher than those recommended (see section 4.2) should be carefully monitored, since renal function impairment (including renal failure) and serum electrolyte (including calcium, phosphorus and magnesium) abnormalities have been observed.
Bolnike, pri katerih se pojavi driska, je treba skrbno opazovati in jim v primeru dehidracije nadomeščati tekočino in elektrolite.
Patients with diarrhoea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated.
Bolnike, zdravljene z zdravilom Teysuno v kombinaciji s cisplatinom, je treba skrbno spremljati, pogosto in redno pa je treba opravljati tudi laboratorijske preiskave, vključno s preiskavo krvi, jetrne funkcije, ledvične funkcije in serumskih elektrolitov.
Patients treated with Teysuno in combination with cisplatin should be closely monitored and laboratory tests, including haematology, liver function, renal function, and serum electrolytes, should be performed frequently.
Bolniki lahko prejmejo drugi odmerek laserske svetlobe 96-120 ur po dajanju zdravila.
Patients may receive a second laser light application 96-120 hours after administration.
Bolniki morajo biti pred dajanjem zdravila Zoledronska kislina Actavis in po njem dobro hidrirani.
Patients must be maintained well hydrated prior to and following administration of Zoledronic acid Actavis.
Bolniki morajo dobivati tudi peroralni dodatek 500 mg kalcija in 400 IE vitamina D na dan.
Patients should also be administered an oral calcium supplement of 500 mg and 400 IU vitamin D daily.
Bolniki morajo prejemati zadostno količino kalcija in vitamina D.
Patients should be adequately supplemented with calcium and vitamin D.
Bolniki morajo prejeti recepte za antiemetična in antidiaroična zdravila.
Patients should be provided with outpatient prescriptions for anti-emetic and anti-diarrhoeal medicinal products.
Bolniki morajo prejeti tudi intramuskularno injekcijo vitamina B12 (1.000 mikrogramov) v tednu pred prvim odmerkom pemetrekseda in enkrat vsake tri cikluse zatem.
Patients must also receive an intramuscular injection of vitamin B12 (1,000 micrograms) in the week preceding the first dose of pemetrexed and once every three cycles thereafter.
Bolniki morajo zdravnika pred pričetkom zdravljenja obvestiti o morebitni hudi okvari jeter.
Patients should inform their doctor before they start treatment if they have severe hepatic disease.
Bolniki ne smejo prehajati s sočasne uporabe zdravil s fenofibratom in pravastatinom na zdravilo Pravafenix (glejte poglavje 5.2).
Patients should not be switched from a free co-administration of fenofibrate and pravastatin preparation to Pravafenix (see section 5.2.).
Bolniki ne smejo upravljati vozil ali strojev po zdravljenju s svetlobo, če so bili pri postopku sedirani.
Patients should not drive or use machines after the light treatment if they have been sedated for the procedure.
Bolniki s Crohnovo boleznijo so od 8. tedna po intravenskemu odmerku približno 6 mg/kg ustekinumaba prejemali 90 mg vzdrževalni odmerek ustekinumaba na 8 ali 12 tednov.
In patients with Crohn’s disease, following an intravenous dose of ~6 mg/kg, starting at week 8, subcutaneous maintenance dosing of 90 mg ustekinumab was administered every 8 or 12 weeks.
Bolniki s popolnim dopolnjevanjem
Fully supplemented patients
Bolniki s psihotičnimi motnjami
Patients with psychotic disorders
Bolniki s telesno maso > 100 kg
Patients with body weight > 100 kg
Bolniki s tveganjem za srčno popuščanje ne smejo biti prekomerno hidrirani.
Overhydration should be avoided in patients at risk of cardiac failure.
Bolniki so dobili povprečno 5 ciklov vzdrževalnega zdravljenja s pemetreksedom in 3,5 cikle placeba.
Patients received a median of 5 cycles of maintenance treatment with pemetrexed and 3.5 cycles of placebo.
Bolniki so morali imeti bodisi spremembe elektrokardiograma (EKG), združljive z novo ishemijo, ali povišano vrednost srčnih encimov ali troponin I ali T na najmanj dvakratno zgornjo mejo normalnega.
Patients were required to have either ECG changes compatible with new ischaemia or elevated cardiac enzymes or troponin I or T to at least twice the upper limit of normal.
Bolniki so potrebovali tudi nižje odmerjanje eritropoetin/darbopoetina (10,4 % proti 18,1 %, p < 0,001), G-CSF/GM-CSF (3,1 % proti 6,1 %, p = 0,004) in pripravkov z železom (4,3 % proti 7,0 %, p = 0,021).
Patients also required lower administration of erythropoietin/darbopoietin (10.4% versus 18.1%, p < 0.001), G-CSF/GM-CSF (3.1% versus 6.1%, p = 0.004), and iron preparations (4.3% versus 7.0%, p = 0.021).
Bolniki so prejeli vzdrževalno zdravljenje do napredovanja bolezni.
Patients received maintenance treatment until disease progression.
Bolniki v obeh skupinah zdravljenja so prejemali popolno dopolnilo s folno kislino in vitaminom B12.
Patients in both study arms were fully supplemented with folic acid and vitamin B12.
Bolniki v teh preskušanjih so imeli PsA diagnosticiran že najmanj 6 mesecev.
Patients in these studies had a diagnosis of PsA for at least 6 months.
Bolniki z atrijsko fibrilacijo morajo klopidogrel dobivati v enem dnevnem odmerku 75 mg.
In patients with atrial fibrillation, clopidogrel should be given as a single daily dose of 75 mg.
Bolniki z blagim do zmernim popuščanjem delovanja ledvic (očistek kreatinina od 45 do 79 ml/min) naj se izogibajo jemanju nesteroidnih protivnetnih zdravil (NSAID), denimo, ibuprofena in acetilsalicilne kisline (> 1,3 g dnevno) 2 dni pred dajanjem pemetrekseda, na dan dajanja in še 2 dni po dajanju pemetrekseda (glejte poglavje 4.5).
Patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min) should avoid taking non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, and aspirin (>1.3 g daily) for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.5).
Bolniki z ledvično boleznijo
Patients with kidney disease
Bolniki z ledvično boleznijo v končnem stadiju, ki zahteva dializo.
End stage renal disease patients requiring dialysis.
Bolniki z ledvično okvaro
Patients with renal impairment
Bolniki z ledvično okvaro (glejte poglavja 4.2, 4.3, 4.4 in 5.2)
Patients with renal impairment (see sections 4.2, 4.3, 4.4, and 5.2)
Bolniki z nezdravljeno hiperkalciemijo imajo na splošno določeno mero okvare ledvic, zato jim je treba natančno kontrolirati delovanje ledvic.
Untreated hypercalcaemia patients generally have some degree of renal function impairment, therefore careful renal function monitoring should be considered.
Bolniki z okvarjenim delovanjem jeter
Patients with hepatic impairment
Bolniki z okvarjenim delovanjem ledvic (po standardni formuli Cockcrofta in Gaulta ali hitrost glomerulne filtracije, izmerjena z metodo Tc99m-DPTA serumskega očistka)
Patients with renal impairment (Standard Cockcroft and Gault formula or glomerular filtration rate measured Tc99m DPTA serum clearance method)
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
Patients with rare hereditory problems of galactose intolerance, the Lapp lactase deficiency or glucose/galactose malabasorption should not take this medicinal product.
Bolniki zdravljeni s pemetreksedom in cisplatinom so potrebovali manj transfuzij (16,4 % proti 28,9 %, p < 0,001), transfuzij rdečih krvničk (16,1 % proti 27,3 %, p < 0,001) in transfuzij krvnih ploščic (1,8 % proti 4,5 %, p = 0,002).
Patients treated with pemetrexed and cisplatin required fewer transfusions (16.4% versus 28.9%, p < 0.001), red blood cell transfusions (16.1% versus 27.3%, p < 0.001) and platelet transfusions (1.8% versus 4.5%, p = 0.002).
Bolniki, ki bi želeli zaploditi otroka, se morajo z zdravnikom posvetovati glede načrtovanja družine oziroma zdravljenja.
Male patients who may wish to father a child should ask their doctor for family planning advice or treatment.
Bolniki, ki jemljejo zdravilo Teysuno, morajo biti obveščeni o nevarnostih in poučeni, da se ob pojavu zmerne ali hude toksičnosti takoj obrnejo na svojega zdravnika.
Patients taking Teysuno should be informed of the risks and instructed to contact their physician immediately if moderate or severe toxicity occurs.
Bolniki, ki prejemajo zdravilo STELARA, lahko v tem času prejmejo inaktivirana ali mrtva cepiva.
Patients receiving STELARA may receive concurrent inactivated or non-live vaccinations.
Bolniki, ki so bili najprej naključno uvrščeni v skupino za prejemanje placeba v 0. ali 4. tednu, pa so prešli v skupino za prejemanje ustekinumaba (bodisi v odmerku 45 mg ali 90 mg) v 12. in 16. tednu.
Patients randomised to receive placebo at Weeks 0 and 4 crossed over to receive ustekinumab (either 45 mg or 90 mg) at Weeks 12 and 16.
Bolniki, ki so bili naključno izbrani za vzdrževalno zdravljenje so morali imeti indeks zmogljivosti po ECOG 0 ali 1.
Patients randomised to maintenance treatment were required to have an ECOG performance status 0 or 1.
Bolniki, ki so bili naključno izbrani za zdravljenje s PDT, so dobivali PhotoBarr v odmerku 2 mg/kg telesne mase s počasno intravensko injekcijo v času 3 do 5 minut.
Patients randomised to treatment with PDT received PhotoBarr at a dose of 2 mg/kg body weight through slow intravenous injection over 3 to 5 minutes.
Bolniki, ki so bili naključno uvrščeni v skupino za prejemanje placeba v 0. in 4. tednu, so prešli na prejemanje ustekinumaba (v odmerku bodisi 45 mg ali 90 mg) v 12. in 16. tednu, potem pa so odmerke prejemali na 12 tednov.
Patients randomised to receive placebo at Weeks 0 and 4 crossed over to receive ustekinumab (either 45 mg or 90 mg) at Weeks 12 and 16 followed by dosing every 12 weeks.
Bolniki, ki so bili naključno uvrščeni v skupino za prejemanje ustekinumaba, so prejeli 45 mg ali 90 mg odmerek v 0. in 4. tednu, potem pa so prejemali enak odmerek na 12 tednov.
Patients randomised to ustekinumab received 45 mg or 90 mg doses at Weeks 0 and 4 and followed by the same dose every 12 weeks.
Bolniki, ki so imeli PASI ≥ 12, PGA ≥ 3 in BSA najmanj 10% ter so bili kandidati za sistemsko terapijo ali fototerapijo, so bili primerni za vključitev v študijo.
Patients with PASI ≥ 12, PGA ≥ 3 and BSA involvement of at least 10%, who were candidates for systemic therapy or phototherapy, were eligible for the study.
Bolniki, ki so kdaj imeli alergijsko in/ali hematološko reakcijo na enega od tienopiridinov, imajo lahko večje tveganje za pojav enake ali druge reakcije na drug tienopiridin.
Patients who had developed a previous allergic reaction and/or haematological reaction to one thienopyridine may have an increased risk of developing the same or another reaction to another thienopyridine.
Bolniki, ki tehtajo več kot 100 kilogramov (kg), lahko prejmejo 90 mg namesto 45 mg.
Patients who weigh more than 100 kilograms (kg) may start on a dose of 90 mg instead of 45 mg.
Bolniki, pri katerih ni zadostnega odziva 8 tednov po prvem subkutanem odmerku, lahko takrat prejmejo drugi subkutani odmerek (glejte poglavje 5.1).
Patients who have not shown adequate response at 8 weeks after the first subcutaneous dose, may receive a second subcutaneous dose at this time (see section 5.1).
Bolniki, pri katerih se je že pojavila zaspanost in/ali nenadna epizoda spanja, ne smejo voziti ali upravljati strojev.
Patients who have experienced somnolence and/or an episode of sudden sleep onset must refrain from driving or operating machines.
Bolniki, primerni za to raziskavo, so morali imeti z biopsijo potrjeno HGD v Barrettovem požiralniku (BP).
Eligible patients for this study were to have biopsy-proven HGD in Barrett’s oesophagus (BO).
Bolniki, starejši od 75 let, so morda bolj ogroženi, kar zadeva neželene učinke, povezane z dihanjem, kot so plevralni izliv in dispneja.
Patients older than 75 years may be at a higher risk of respiratory related adverse events such as pleural effusion and dyspnoea
Bolniki, stari 65 let ali več
Patients aged 65 years and over
Bolniki, stari 65 let ali več, lahko dobivajo zdravilo Zoledronska kislina Actavis.
Zoledronic acid Actavis can be given to people aged 65 years and over.
bolnikih z metastatskim karcinomom jajčnikov po neuspehu z zdravili prvega ali naslednjega izbora bolnikih z relapsom drobnoceličnega pljučnega raka, pri katerih ponovno zdravljenje s terapijo prve izbire ni primerno (glejte poglavje 5.1).
patients with metastatic carcinoma of the ovary after failure of first line or subsequent therapy. patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate (see section 5.1).
bolnikih z metastatskim karcinomom jajčnikov po neuspehu z zdravili prvega ali naslednjega izbora. bolnikih z relapsom drobnoceličnega pljučnega raka, pri katerih ponovno zdravljenje s terapijo prve izbire ni primerno (glejte poglavje 5.1).
patients with metastatic carcinoma of the ovary after failure of first line or subsequent therapy. patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate (see section 5.1).
bolnikih, ki imajo v anamnezi hudo preobčutljivostno reakcijo na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1,
have a history of severe hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Bolnikom ali njihovim skrbnikom naročite, naj si injicirajo predpisano količino zdravila STELARA v skladu z navodilom za uporabo.
Patients or their caregivers should be instructed to inject the prescribed amount of STELARA according to the directions provided in the package leaflet.
Bolnikom in negovalcem je treba povedati, da se lahko pri bolnikih, ki se zdravijo z dopaminskimi agonisti, tudi z zdravilom Pramipeksol Accord , pojavijo vedenjski simptomi motenj nadzora impulzov, kot so patološko hazardiranje, povečan libido, hiperseksualnost, kompulzivno trošenje denarja ali nakupovanje, prenajedanje in kompulzivno uživanje hrane.
Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists, including Pramipexole Accord.
Bolnikom je treba pred vsakim odmerkom zdravila Zoledronska kislina Actavis določiti koncentracijo serumskega kreatinina.
Patients should have their serum creatinine levels assessed prior to each dose of Zoledronic acid Actavis.
Bolnikom je treba svetovati, da se posvetujejo z oftalmologom, če opazijo kakršne koli spremembe vida po zdravljenju s PhotoBarrom PDT.
Patients should be advised to consult their ophthalmologist if they notice any vision changes after treatment with PhotoBarr PDT.
Bolnikom moramo povedati, da lahko pride do halucinacij (večinoma vidnih).
Patients should be informed that (mostly visual) hallucinations can occur.
Bolnikom naročite, naj se posvetujejo z zdravnikom, če se pojavijo znaki ali simptomi, ki kažejo na okužbo.
Patients should be instructed to seek medical advice if signs or symptoms suggestive of an infection occur.
Bolnikom s TIH in serumskim kreatininom < 400 mikromolov/l ali < 4,5 mg/dl odmerka ni treba prilagoditi (glejte poglavje 4.4).
No dose adjustment is necessary in TIH patients with serum creatinine < 400 micromol/l or < 4.5 mg/dl (see section 4.4).
Bolnikom se lahko nato zdravilo odmerja na 8 ali 12 tednov, odvisno od klinične presoje (glejte poglavje 5.1).
Patients may subsequently be dosed every 8 weeks or every 12 weeks according to clinical judgment (see section 5.1).
Bolnikom z očistkom kreatinina manjšim kot 20 ml/min damo dnevni odmerek zdravila Pramipeksol Accord v enkratnem odmerku, pri čemer začnemo z dajanjem 0,088 mg pramipeksola (0,125 mg soli) dnevno.
In patients with a creatinine clearance less than 20 ml/min, the daily dose of Pramipexole Accord should be administered in a single dose, starting at 0.088 mg of base (0.125 mg of salt) daily.
Bolnikom, ki izgubili odziv pri odmerjanju na 12 tednov, lahko koristi zvečanje pogostosti odmerjanja na vsakih 8 tednov (glejte poglavje5.1).
Patients who lose response on dosing every 12 weeks may benefit from an increase in dosing frequency to every 8 weeks (see section 5.1).
Bolnikom, ki prejemajo zdravilo Zoledronska kislina Actavis, je treba izročiti navodilo za uporabo in opozorilno kartico za bolnika.
Patients treated with Zoledronic acid Actavis should be given the package leaflet and the patient reminder card.
Bolnikom, ki se jim med zdravljenjem poslabša delovanje ledvic, je treba zdravilo Zoledronska kislina Actavis ukiniti.
In patients who show evidence of renal deterioration during treatment, Zoledronic acid Actavis should be withheld.
Bolnikov se NE sme zdraviti s porfirini, če:
Patients should NOT be treated with porfimer if:
Bolnišnični farmacevt, medicinska sestra ali zdravnik bo prašek Pemetreksed Hospira, preden ga boste prejeli, zmešal z 9 mg/ml (0,9 %) raztopino natrijevega klorida za injiciranje.
A hospital pharmacist, nurse or doctor will have mixed the Pemetrexed Hospira powder with 9 mg/ml (0.9 %) sodium chloride solution for injection before it is given to you.
Bondenza 150 mg веднъж месечно (N = 320)
Bondenza 150 mg once monthly (N=320)
Bondenza 150 mg филмирани таблетки
Bondenza 150 mg film-coated tablets
Bondenza 150 mg филмирани таблетки Ибандронова киселина
Bondenza 150 mg film-coated tablets Ibandronic acid
Bondenza 3 mg инжекционен разтвор
Bondenza 3 mg solution for injection
Bondenza 3 mg инжекционен разтвор Ибандронова киселина
Bondenza 3 mg solution for injection Ibandronic acid
Bondenza 3 mg инжекционен разтвор ибандронова киселина (ibandronic aсid)
Bondenza 3 mg solution for injection ibandronic acid
Bondenza може да прекрати костната загуба чрез спиране на по-нататъшната загуба на костно вещество и увеличаване на костната маса при повечето жени, които го приемат, макар че те няма да могат да видят или почувстват разликата.
Bondenza may reverse bone loss by stopping more loss of bone and increasing bone mass in most women who take it, even though they won’t be able to see or feel a difference.
Bondenza не е изследван при педиатричната популация, поради това няма данни за ефикасността или безопасността при тази популация пациенти.
Bondenza was not studied in the paediatric population, therefore no efficacy or safety data are available for this patient population
Bondenza не е изследван при педиатричната популация, поради това няма данни за ефикасността или безопасността при тази популация пациенти.
Bondenza was not studied in the paediatric population, therefore no efficacy or safety data are available for this patient population.
Bondenza не трябва да се използва в периода на кърмене.
Bondenza should not be used during breast-feeding.
Bondenza не трябва да се използва при деца или юноши на възраст под 18 години.
Bondenza must not be used in children or adolescents below 18 years.
Bondenza се предлага в опаковки с 1 предварително напълнена спринцовка и 1 инжекционна игла или предварително напълнени спринцовки и 4 инжекционни игли.
Bondenza is available in packs of 1 pre-filled syringe and 1 injection needle or 4 pre-filled syringes and 4 injection needles.
Bondenza съдържа по-малко от 1 mmol натрий (23 mg) на доза (3 ml), т.e. практически не съдържа натрий.
Bondenza contains less than 1 mmol sodium (23 mg) per dose (3 ml), i.e. essentially “sodium- free”.
Bondronat 2 mg концентрат за инфузионен разтвор
Bondronat 2 mg concentrate for solution for infusion.
Bondronat 2 mg концентрат за инфузионен разтвор Ибандронова киселина
Bondronat 2 mg concentrate for solution for infusion ibandronic acid
Bondronat 2 mg концентрат за инфузионен разтвор Ибандронова киселина i.v. приложение
Bondronat 2 mg concentrate for solution for infusion ibandronic acid
Bondronat 50 mg филмирани таблетки
Bondronat 50 mg film-coated tablets.
Bondronat 50 mg филмирани таблетки Ибандронова киселина
Bondronat 50 mg film-coated tablets ibandronic acid
Bondronat 6 mg концентрат за инфузионен разтвор
Bondronat 6 mg concentrate for solution for infusion.
Bondronat 6 mg концентрат за инфузионен разтвор Ибандронова киселина
Bondronat 6 mg concentrate for solution for infusion ibandronic acid
Bondronat 6 mg концентрат за инфузионен разтвор Ибандронова киселина i.v. приложение
Bondronat 6 mg concentrate for solution for infusion ibandronic acid
Bondronat е безцветен, бистър разтвор.
Bondronat is a colourless, clear solution.
Bondronat е проучен и при лечението на тумор-индуцирана хиперкалциемия в три четириседмични проучвания, обхващащи общо 343 пациенти.
Bondronat has also been studied in the treatment of hypercalcaemia caused by tumours in three four- week studies involving a total of 343 patients.
Bondronat концентрат за инфузионен разтвор трябва да се прилага под формата на интравенозна инфузия.
Bondronat concentrate for solution for infusion should be administered as an intravenous infusion.